Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Rocco

Orthopaedic Surgery Washington Terrace, UT Medical Doctor

NPI 1306818190 CMS profile 149516

5782 Adams Avenue Parkway, Washington Terrace, UT 84405

Open in the dashboard

General payments

$30,488

409 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,800 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Jeffrey Rocco of Washington Terrace, UT is reported in the CMS Open Payments database as having received $30,488 across 409 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $13,800 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,098 41
2024 General $9,645 67
2023 General $1,806 45
2022 General $5,834 67
2021 General $3,362 43
2020 General $2,778 94
2019 General $3,964 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Rocco
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jeffrey Rocco were reported at $3,098. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jeffrey Rocco Orthopaedic Surgery median Middle half National median
2019 $3,964 $644 $140–$2,844 $163
2020 $2,778 $312 $75–$1,860 $114
2021 $3,362 $520 $117–$2,495 $132
2022 $5,834 $598 $128–$2,731 $149
2023 $1,806 $461 $128–$2,264 $160
2024 $9,645 $497 $134–$2,475 $164
2025 $3,098 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. MicroPort Orthopedics Inc $4,652 24 payments
  2. Stryker Corporation $4,393 24 payments
  3. Medacta USA, Inc. $4,079 19 payments
  4. Encore Medical, LP $3,562 16 payments
  5. Smith+Nephew, Inc. $3,497 32 payments
  6. Radius Health, Inc. $2,981 173 payments
  7. Active Medical, LLC $1,200 1 payment
  8. Think Surgical, Inc. $916 5 payments
  9. Bioventus LLC $736 9 payments
  10. Zimmer Biomet Holdings, Inc. $712 9 payments
  11. Other $3,760 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $16,198 53 payments
  2. Food and Beverage $11,725 353 payments
  3. Honoraria $1,320 1 payment
  4. Education $1,245 2 payments
Products named General payments · program years 2019–2025
  1. MPO Medial Pivot Knee $3,814 16 payments
  2. REAL INTELLIGENCE $2,237 26 payments
  3. MAKO $2,112 7 payments
  4. Tymlos $2,110 132 payments
  5. GMK Sphere Revision System $2,066 5 payments
  6. PROSTEP $1,496 3 payments
  7. GMRS $1,448 4 payments
  8. TRIDENT $1,448 4 payments
  9. ACCOLADE $1,408 3 payments
  10. DJO SURGICAL $1,404 10 payments
  11. Other $16,185 246 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

150

Median for Orthopedic Surgery: 203

Drug cost

$1,075

Median for Orthopedic Surgery: $1,433

Branded share of claims

30%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 79 $373
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 31 $360
Cephalexin Generic 12 $130
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $126
Gabapentin Generic 14 $86

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$113,588

Of which drugs: $29,820

Medicare patients

250

Average age 74

Services billed

3,134

172 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
Osteoporosis 64%
High blood pressure 63%
Chronic kidney disease 30%
Depression 30%
Diabetes 24%
Ischemic heart disease 22%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 16 28 $15,258
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 15 1,440 $7,473
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 29 79 $379

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STRENSIQ
  • Alexion Pharmaceuticals, Inc. $153
$153 — —
Tymlos
  • Radius Health, Inc. $50
$50 — —
Crysvita
  • Kyowa Kirin, Inc. $39
$39 — —
EVENITY
  • Amgen Inc. $13
$13 — —
Prolia
  • Amgen Inc. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

409 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record